Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

Journal of Clinical Investigation

Volumn 121, Issue 7, 2011, Pages 2921-2931

  Rayner, Katey J ^a   Sheedy, Frederick J ^a   Esau, Christine C ^b   Hussain, Farah N ^a   Temel, Ryan E ^c   Parathath, Saj ^a   Van Gils, Janine M ^a   Rayner, Alistair J ^a   Chang, Aaron N ^b   Suarez, Yajaira ^a   Fernandez Hernando, Carlos ^a   Fisher, Edward A ^a   Moore, Kathryn J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGULUS THERAPEUTICS   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 3 HYDROXYACYL COENZYME A DEHYDROGENASE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANTISENSE OLIGONUCLEOTIDE; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; MICRORNA; MICRORNA 33; PROTEIN CROT; PROTEIN INSIG1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; FECES; GENE EXPRESSION; LIPID COMPOSITION; LIPID METABOLISM; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; REMISSION; REVERSE CHOLESTEROL TRANSPORT;

ANIMALS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, HDL; GENE EXPRESSION; HUMANS; LIPID METABOLISM; LIVER; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; RANDOM ALLOCATION; RECEPTORS, LDL;

EID: 79960015327     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57275     Document Type: Article

References (73)

1. Castelli WP, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977;55(5):767-772. (Pubitemid 8090093)
2. Wilson PW. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990;66(6):7A-10A.
3. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353(6341):265-267. (Pubitemid 21896769)
4. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94(2):899-903.
5. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91(20):9607- 9611. (Pubitemid 24297964)
6. Choudhury RP, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol. 2004;24(10):1904-1909. (Pubitemid 39350311)
7. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100(17):1816-1822. (Pubitemid 29498389)
8. Rong JX, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104(20):2447-2452. (Pubitemid 33108379)
9. Shah PK, et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103(25):3047-3050. (Pubitemid 32587849)
10. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85(4):1234-1241. (Pubitemid 20123768)
11. Nissen SE, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama. 2003;290(17):2292-2300. (Pubitemid 37430562)
12. Brooks-Wilson A, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22(4):336-345. (Pubitemid 29369523)
13. Bodzioch M, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22(4):347-351. (Pubitemid 29369524)
14. Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006;99(10):1031-1043. (Pubitemid 44729927)
15. Kennedy MA, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1(2):121-131. (Pubitemid 43977167)
16. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004;101(26):9774-9779. (Pubitemid 38869312)
17. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7(5):365-375. (Pubitemid 351598023)
18. Wang X, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117(8):2216-2224. (Pubitemid 47219566)
19. Out R, et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2008;28(2):258-264. (Pubitemid 351161197)
20. Yvan-Charvet L, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117(12):3900-3908. (Pubitemid 350224099)
21. Adorni MP, et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res. 2007;48(11):2453-2462. (Pubitemid 350058756)
22. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17(6):985-993. (Pubitemid 36683707)
23. Joseph SB, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99(11):7604-7609. (Pubitemid 34568738)
24. Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J Lipid Res. 2009;50(2):301-311.
25. Feig JE, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest. 2010;120(12):4415-4424.
26. Naik SU, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113(1):90-97. (Pubitemid 43958493)
27. Bradley MN, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest. 2007;117(8):2337-2346. (Pubitemid 47219578)
28. Rayner KJ, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570-1573.
29. Najafi-Shoushtari SH, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328(5985):1566-1569.
30. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A. 2010;107(27):12228-12232.
31. Davis S, et al. Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res. 2009;37(1):70-77.
32. Elmen J, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896-899. (Pubitemid 351550859)
33. Lanford RE, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201.
34. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther. 2000;292(2):468-479. (Pubitemid 30067408)
35. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115(10):2870-2874. (Pubitemid 41434414)
36. Wang X, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117(8):2216-2224. (Pubitemid 47219566)
37. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2009;5(4):381-391.
38. Feig JE, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A. 2011;108(17):7166-7171.
39. Horie T, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A. 2010;107(40):17321-17326.
40. Gerin I, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010;285(44):33652- 33661.
41. Dávalos A, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling [published online ahead of print May 16, 2011]. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1102281108.
42. Yvan-Charvet L, et al. Cholesterol efflux potential and antiinflammatory properties of highdensity lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30(7):1430-1438.
43. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006;116(5):1435-1442.
44. Innerarity TL, Pitas RE, Mahley RW. Modulating effects of canine high density lipoproteins on cholesteryl ester synthesis induced by beta-very low density lipoproteins in macrophages. Possible in vitro correlates with atherosclerosis. Arteriosclerosis. 1982;2(2):114-124. (Pubitemid 12084412)
45. Khera AV, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.
46. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50 suppl:S189-S194.
47. Sun Y, et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res. 2009;104(4):455-465.
48. Feig JE, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation. 2011;123(9):989-998.
49. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23-35. (Pubitemid 37328697)
50. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol. 2001;21(5):399-425. (Pubitemid 34259913)
51. Aiello RJ, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22(4):630-637. (Pubitemid 34408745)
52. Van Eck M, et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26(4):929-934. (Pubitemid 43732174)
53. Vaisman BL, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001;108(2):303-309. (Pubitemid 32656254)
54. Joyce CW, et al. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of proatherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem. 2006;281(44):33053-33065. (Pubitemid 46036688)
55. Singaraja RR, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110(1):35-42. (Pubitemid 34743463)
56. Esau C, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87-98.
57. Elmen J, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36(4):1153-1162. (Pubitemid 351330933)
58. Baigent C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
59. Kearney PM, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.
60. Barter P, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-1310. (Pubitemid 47481452)
61. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055-2060. (Pubitemid 35192810)
62. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512-3517. (Pubitemid 39612564)
63. Tardif JC, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675-1682.
64. Cannon CP, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-2415.
65. Rader DJ. Illuminating HDL--is it still a viable therapeutic target? N Engl J Med. 2007;357(21):2180-2183. (Pubitemid 350146114)
66. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356(13):1364-1366. (Pubitemid 46513305)
67. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27(2):257-260. (Pubitemid 46143036)
68. Stewart CR, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11(2):155-161.
69. Moore KJ, et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005;115(8):2192-2201. (Pubitemid 41134161)
70. Manning-Tobin JJ, et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2009;29(1):19-26.
71. Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, Fisher EA. Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2002;99(4):2234-2239. (Pubitemid 34169044)
72. Trogan E, Fisher EA. Laser capture microdissection for analysis of macrophage gene expression from atherosclerotic lesions. Methods Mol Biol. 2005;293:221-231.
73. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185-193. (Pubitemid 36181903)